Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 20 |
| Active Pipeline (Recruiting Now) | 15 (12) |
| Completed vs Stopped Early | 4 / 1 (5.0%) |
| Median Closed Actual Enrollment | 43 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Nationwide Children's Hospital | Columbus, OH | 19 |
| Children's National Medical Center | Washington D.C, DC | 8 |
| Children's Hospital Colorado | Aurora, CO | 8 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05286788 | MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Phase II | RECRUITING |
| NCT05843253 | Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant | Phase II | RECRUITING |
| NCT05267821 | Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS | Phase II/III | RECRUITING |
| NCT05096481 | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Phase II | RECRUITING |
| NCT06838676 | ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Nationwide Children's Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.